22.418 articles found

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

MUELLER ALAN L, MOE SCOTT T.

· 2006-02-13

Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.

Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R.

Brain · 2006-02-13

DOI: 10.1093/brain/awl031PMID: 16476674

Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.

Sossi V, de la Fuente-Fernández R, Schulzer M, Adams J, Stoessl J.

Brain · 2006-02-13

DOI: 10.1093/brain/awl028PMID: 16476675

A PHARMACEUTICAL COMPOSITION CONTAINING OBOVATOL AS AN ACTIVE INGREDIENT FOR PREVENTION AND TREATMENT NEURODEGENERATIVE DISEASES

KWON BYOUNG MOG, SON KWANG HEE, HAN DONG CHO, LEE JI MIN, SUK KYOUNG HO, HONG SU HYUNG, OCK JI YEON.

· 2006-02-08

Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease.

Trost M, Su S, Su P, Yen RF, Tseng HM, Barnes A, Ma Y, Eidelberg D.

Neuroimage · 2006-02-08

DOI: 10.1016/j.neuroimage.2005.12.024PMID: 16466936

Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.

Hesse S, Oehlwein C, Barthel H, Schwarz J, Polster D, Wagner A, Sabri O.

J Neural Transm (Vienna) · 2006-02-06

DOI: 10.1007/s00702-005-0401-6PMID: 16463120

THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN.

KYLE DONALD J.

· 2006-02-01

A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.

Ritchie CW, Chiu E, Harrigan S, MacFarlane S, Mastwyk M, Halliday G, Hustig H, Hall K, Hassett A, O'Connor DW, Opie J, Nagalingam V, Snowdon J, Ames D.

Int J Geriatr Psychiatry · 2006-02-01

DOI: 10.1002/gps.1446PMID: 16416458

Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations.

Tan EK.

Eur J Neurol · 2006-02-01

DOI: 10.1111/j.1468-1331.2006.01447.xPMID: 16417600

Measuring therapy adherence in Parkinson's disease: a comparison of methods.

Grosset KA, Bone I, Reid JL, Grosset D.

J Neurol Neurosurg Psychiatry · 2006-02-01

DOI: 10.1136/jnnp.2005.064709PMID: 16421131

Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.

Samadi P, Grégoire L, Rouillard C, Bédard PJ, Di Paolo T, Lévesque D.

Ann Neurol · 2006-02-01

DOI: 10.1002/ana.20738PMID: 16437566

Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.

Stocchi F.

Int J Clin Pract · 2006-02-01

DOI: 10.1111/j.1742-1241.2006.00806.xPMID: 16451296